Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022

Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference

US FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome

Anavex Life Sciences Announces Late-Breaking Presentation at the 2022 CTAD Congress

Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders

Anavex Life Sciences to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022